Slide 1: Innovative ADCs with a New Payload: Amanitin
INNOVATIVE ADCs WITH A NEW PAYLOAD: AMANITIN FY 2025 Financial Results & Business Update • 26 March 2026
Slide 2: Safe Harbor: Forward Looking Statements
SAFE HARBOR FORWARD LOOKING STATEMENTS This communication contains certain forward-looking statements, competition from other biopharmaceutical, chemical and relating to the Company’s business, which can be identified by the pharmaceutical companies, environmental, health and safety matters, use of
Slide 3: Corporate Highlights
CORPORATE HIGHLIGHTS PROPRIETARY PAYLOADS, WHOLLY-OWNED ASSETS & PARTNERED ADCs Our Company Complete GMP Manufacturing Supply Chain • Clinical-stage biotech • Heidelberg Pharma Group: 120 employees – 30 Nov 2025 Technology and Asset Partnerships Maximize ~ 35 employees – currently Value of Pipeline
Slide 4: Situation End of September 2025
SITUATION END OF SEPTEMBER 2025 • Heidelberg Pharma monetized part of the potential royalty streams from TLX250-Px (out-licensed to Telix Pharmaceuticals) - and built its financing strategy around this • USD 70 million milestone payment due upon FDA approval of TLX250-Px and monies planned to be use
Slide 5: Cost-Saving Measures Decided in September 2025
COST-SAVING MEASURES DECIDED IN SEPTEMBER 2025 COST-SAVING MEASURES • Focus on lead program: Clinical Phase I/IIa trial with HDP-101 in Multiple Myeloma will continue as planned • In Q2 initiated Phase I trial with ADC candidate HDP-102 in Non-Hodgkin Lymphoma has been put on hold • Preparations for
Slide 6: Financials
FINANCIALS © Heidelberg Pharma AG 6
Slide 7: Amendment with Healthcare Royalty (March 2026) and Participation of Soleus Capital
AMENDMENT WITH HEALTHCARE ROYALTY (MARCH 2026) AND PARTICIPATION OF SOLEUS CAPITAL Partial monetization of royalty stream for TLX250-Px in the field of diagnostic use Key terms of the newly amended agreement between Heidelberg Pharma, HealthCare Royalty and Soleus Capital: • USD 20 million upfront p
Slide 8: Profit and Loss 2025
PROFIT AND LOSS 2025 Guidance Operating expenses In € m FY 2025 FY 2024 10/2025 5% 1% Sales revenue and other income 7.5 – 9.0 6.9 12.0 15% Operating expenses (36.0) – (40.0) (49.0) (32.6) Cost of sales (0.3) (1.8) R&D costs (38.7) (21.8) Administrative costs (7.6) (6.7) 79% Other expenses (2.4) (2.
Slide 9: Balance Sheet as of 30 November 2025
BALANCE SHEET AS OF 30 NOVEMBER 2025 Assets (€ m) 30.11.2025 30.11.2024 Equity and liabilities (€ m) 30.11.2025 30.11.2024 Non-current assets 9.8 13.2 Non-current liabilities 37.8 21.8 Other current assets 13.3 18.1 Current liabilities 11.2 8.0 Cash 15.0 29.4 Equity (10.9) 30.9 38.1 60.7 38.1 60.7 •
Slide 10: Financing and Cash Flow as of 30 November 2025
FINANCING AND CASH FLOW AS OF 30 NOVEMBER 2025 Financing activities in 2025 • Cash inflow of EUR 18.4 million (USD 20 million) due to the transaction with HealthCare Royalty (HCRx), amendment March 2025 Cash Flow in € m FY 2025 FY 2024 Operating activities (31.6) (29.6) Investing activities (0.1) (0
Slide 11: Guidance 2026
GUIDANCE 2026 In € m FY 2025 Guidance 2026 Sales revenue and other income 6.9 11.0 – 15.0 Operating expenses (49.0) (25.0) – (29.0) Operating result (42.1) (13.0) – (17.0) Change in cash funds (14.4) 0.0 – (4.0) Change in cash funds per month (1.2) 0.0 – (0.3) © Heidelberg Pharma AG 11
Slide 12: R&D Update – Focus on HDP-101
R&D UPDATE – FOCUS ON HDP-101 INN: PAMLECTABART TISMANITIN © Heidelberg Pharma AG 12
Slide 13: Lead Program: Pamlectabart Tismanitin in Multiple Myeloma
LEAD PROGRAM: PAMLECTABART TISMANITIN IN MULTIPLE MYELOMA MULTIPLE MYELOMA (MM) IS A TYPE OF BLOOD CANCER PHASE I/IIa CLINICAL TRIAL • … that develops from plasma cells in the bone marrow and can affect more than one part of the body. Phase I part: dose escalation (ongoing) • Cohorts of 2-6 patients
Slide 14: Pamlectabart Tismanitin – Phase I Preliminary Efficacy Data (Cohort 8)
PAMLECTABART TISMANITIN – PHASE I PRELIMINARY EFFICACY DATA (COHORT 8) Cohort 8 Progressive disease (PD) Stable disease (SD) (140 µg/kg) Minimal response (MR) Partial response (PR) Very good partial response (VGPR) Stringent complete response (CR) 10101_P40 C Not evaluable 10101_P37 C Ongoing treatm
Slide 15: Objective Response Rates (ORR)
OBJECTIVE RESPONSE RATES (ORR) 70% PRELIMINARY EFFICACY 60% 57% • Multiple responses were seen (from 90 µg/kg) across 50% different dosing arms, confirming that changes in the dose distribution maintained the anti-tumor effect while 40% 38% 29% improving drug tolerability • We observed 38% ORR in Co
Slide 16: Phase I/IIa: No Safety Issues & Well Tolerated at All Dose Levels
PAMLECTABART TISMANITIN PHASE I/IIa: NO SAFETY ISSUES & WELL TOLERATED AT ALL DOSE LEVELS Safety of Cohort 9 dose has been confirmed, data evaluation ongoing Safety & tolerability at all dose levels evaluated (Cohort 1-9): • MTD has not been reached up to Cohort 9 • No signs of ocular toxicity, infu
Slide 17: Heidelberg Pharma & Partners: Status Update & Expected Milestones
HEIDELBERG PHARMA & PARTNERS: STATUS UPDATE & EXPECTED MILESTONES HDP-101 HDP-102 HDP-103 HDP-104 Partner programs (pamlectabart tismanitin) BCMA-ATAC CD37-ATAC PSMA-ATAC GCC-ATAC Takeda: ATAC against an for r/r Multiple Myeloma for Non-Hodgkin for mCR Prostate for colorectal cancer undisclosed targ
Slide 18: Good Reasons to Invest in Heidelberg Pharma
GOOD REASONS TO INVEST IN HEIDELBERG PHARMA HDP-101 positive efficacy data Highly dynamic ADC environment and good tolerability in RRMM are with an attractive global market a validation of our Amanitin based that is expected to grow technology for future indications to USD 32 billion in 2033 As the
Slide 19: Thank You for Your Attention!
THANK YOU FOR YOUR Heidelberg Pharma AG Ladenburg, Germany Tel.: +49 6203 10090 ATTENTION! investors@hdpharma.com investors@hdpharma.com www.heidelberg-pharma.com www.heidelberg-pharma.com